Equities analysts predict that Omeros Co. (NASDAQ:OMER) will report earnings per share of ($0.16) for the current quarter, according to Zacks. Two analysts have made estimates for Omeros’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.18). Omeros posted earnings of ($0.20) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 20%. The business is expected to issue its next earnings results on Thursday, March 15th.

According to Zacks, analysts expect that Omeros will report full-year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.01) to ($0.95). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.49) per share, with EPS estimates ranging from ($0.70) to ($0.24). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Omeros.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to the consensus estimate of $17.82 million. Omeros’s quarterly revenue was up 91.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.34) EPS.

A number of equities analysts have recently commented on OMER shares. Cowen lowered shares of Omeros from an “outperform” rating to a “market perform” rating in a report on Thursday, November 2nd. Maxim Group set a $24.00 price target on shares of Omeros and gave the stock a “buy” rating in a report on Friday, October 20th. Zacks Investment Research raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. HC Wainwright started coverage on shares of Omeros in a report on Wednesday, November 8th. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $47.00 target price on shares of Omeros in a report on Tuesday, November 28th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Omeros currently has an average rating of “Buy” and a consensus price target of $34.14.

Shares of Omeros (NASDAQ:OMER) traded up $0.07 during trading hours on Friday, hitting $19.37. 398,019 shares of the stock were exchanged, compared to its average volume of 882,683. The company has a market cap of $929.83, a price-to-earnings ratio of -15.02 and a beta of 3.56. Omeros has a 1 year low of $8.71 and a 1 year high of $27.09. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99.

Several hedge funds have recently added to or reduced their stakes in OMER. First Interstate Bank bought a new position in shares of Omeros during the 3rd quarter valued at $108,000. Legal & General Group Plc boosted its position in Omeros by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 751 shares during the period. Hanseatic Management Services Inc. boosted its position in Omeros by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 10,592 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in Omeros during the 3rd quarter valued at $256,000. Finally, SG Americas Securities LLC boosted its position in Omeros by 138.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 7,067 shares during the period. 49.71% of the stock is currently owned by institutional investors.

WARNING: “” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.themarketsdaily.com/2018/01/10/1214211.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply